Literature DB >> 2388286

Interleukin-2: further progress through greater understanding.

D R Parkinson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2388286     DOI： 10.1093/jnci/82.17.1374

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  3 in total

1.  Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.

Authors:  Z Gazit; D W Weiss; D Shouval; M Yechezkeli; V Schirrmacher; M Notter; J Walter; E Kedar
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Persistent augmentation of natural-killer- and T-cell-mediated cytotoxicity in peripheral blood mononuclear cells pulsed in vitro with high-dose recombinant interleukin-2 prior to culturing with a low maintenance dose.

Authors:  P A Palmer; J G Scharenberg; B M von Blomberg; A G Stam; C J Meijer; G J Roest; C R Franks; R J Scheper
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

3.  High-dose continuous venous infusion of interleukin-2: influence of dose and infusion rate on tumoricidal function and lymphocyte subsets.

Authors:  W C Mertens; D Banerjee; N al-Mutter; L Stitt; V H Bramwell; P K Lala
Journal:  Cancer Immunol Immunother       Date:  1995-11       Impact factor: 6.968
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.